Division of Hematology/Oncology

Faculty

faculty photo

Lynn Mara Schuchter, M.D.

C. Willard Robinson Professor of Hematology-Oncology
Attending Physician, Hospital of the University of Pennsylvania
Program Leader: Melanoma Program, Abramson Cancer Center of the University of Pennsylvania
Division Chief, Hematology-Oncology, University of Pennsylvania
Department: Medicine

Contact information
Hospital of the University of Pennsylvania
3400 Spruce Street, 1218 Penn Tower
Philadelphia, PA 19104
Office: 215-662-4859
Fax: 215-349-5866
Education:
B.S.
University of Michigan, 1978.
M.D.
Chicago Medical School, 1982.
Post-Graduate Training
Intern, Department of Medicine , Michael Reese Hospital, Chicago, IL, 1982-1983.
Resident, Department of Medicine, Michael Reese Hospital, Chicago, IL, 1983-1985.
Chief Medical Resident, Department of Medicine, Michael Reese Hospital, Chicago, IL, 1985-1986.
Clinical Fellow, Medical Oncology, The Johns Hopkins Oncology Center Baltimore, MD, 1986-1989.
Visiting Fellow, Biologic Response Modifier Program, NCI, Frederick, MD, 1987-1987.
Certifications
American Board of Internal Medicine (Internal Medicine) , 1986.
American Board of Internal Medicine Subspecialty Certification in Medical Oncology, 1990.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA. : The FBXO4 Tumor Suppressor Functions as a Barrier to BrafV600E-Dependent Metastatic Melanoma. Mol Cell Biol. 33(22): 4422-33, November 2013.

Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu X, Fraker D, Schuchter LM, Czerniecki BJ, Karakousis G. : Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol. 20(11): 3610-7, October 2013 Notes: Epub 2013 Jul 10.

Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X, Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC. : Clark Level Risk Stratifies Patients with Mitogenic Thin Melanomas for Sentinel Lymph Node Biopsy. Ann Surg Oncol. October 2013.

O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT. : Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. October 2013 Notes: Epub ahead of print.

Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL. : Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4(6): 1090-9, September 2013 Notes: Epub 2013 Sep 19.

Lynn Mara Schuchter, Ragini Reiney Kudchadkar, Rene Gonzalez, Donald P. Lawrence, Jeffrey Alan Sosman, Jeffrey R. Infante, Adil Daud, Richard Kefford, Jonathan S. Cebon, William Howard Sharfman, Ravi K. Amaravadi, Peter D. Boasberg, Karl D. Lewis, Keith Flaherty, Danielle Ouellet, Shonda M Little, Jennifer Clark, Geoffrey Thomas Gibney, Kiran Patel, Omid Hamid; University of Pennsylvania, Philadelphia, PA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; UCHSC, Anschultz Cancer Pavilion, Aurora, CO; Massachusetts General Hospital Cancer Center, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; University of California, San Francisco, San Francisco, CA; Westmead Hospital and Melanoma Institute Australia, Westmead, Australia; Austin Health, Melbourne, Australia; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Cancer Center, Aurora, CO; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Collegeville, PA; Moffitt Cancer Center, Tampa, FL; The Angeles Clinic and Research Institute, Los Angeles, CA : Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM). J Clin Oncol June 2013 Notes: (suppl; abstr 9066)

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. : Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 31(14): 1767-74, May 2013.

Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK: Physician and stakeholder perceptions of conflict of interest policies in oncology. J Clin Oncol. 31(13): 1677-82, May 2013 Notes: Epub 2013 Mar 25.

Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W,Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest. 123(5): 2155-68, May 2013 Notes: Epub 2013 Apr 1.

Glanz K, Volpicelli K, Kanetsky PA, Ming ME, Schuchter LM, Jepson C, Domchek SM, Armstrong K.: Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev. 22(459): 607-14, Apr 2013 Notes: Epub 2013 Feb 7.

back to top
Last updated: 08/05/2014
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter